PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement

PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement

Introduction: There are currently three first-line immunotherapy options used as monotherapy in advanced non-small cell lung cancer (NSCLC) patients with high programmed death ligand 1 (PD-L1) expression (≥50%). This manuscript aims to evaluate the available data on atezolizumab (AT), cemiplimab (CE...

Full description

Bibliographic Details
Main Authors: Dolores Isla, Alfredo Sánchez, Joaquín Casal, Manuel Cobo, Margarita Majem, Noemi Reguart, Jon Zugazagoitia, Reyes Bernabé
Format: Article
Language:English
Published: MDPI AG 2023-08-01
Series:Journal of Clinical Medicine
Subjects:
lung cancer
non-small cell lung cancer
immunotherapy
first-line treatment
PD-(L)1 inhibitors
efficacy
Online Access:https://www.mdpi.com/2077-0383/12/15/5063

Internet

https://www.mdpi.com/2077-0383/12/15/5063

Similar Items